Daxor Corporation (NASDAQ:DXR – Get Free Report) was the recipient of a significant decrease in short interest in July. As of July 31st, there was short interest totaling 348 shares, a decrease of 76.4% from the July 15th total of 1,472 shares. Based on an average daily trading volume, of 1,908 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company’s stock are sold short.
Hedge Funds Weigh In On Daxor
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Osaic Holdings Inc. bought a new stake in Daxor during the 2nd quarter valued at $86,000. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Daxor in the fourth quarter worth $184,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in shares of Daxor during the first quarter valued at about $245,000. Crescent Grove Advisors LLC bought a new stake in shares of Daxor during the first quarter valued at about $104,000. Finally, Aristides Capital LLC acquired a new stake in Daxor in the first quarter worth about $403,000. 1.34% of the stock is owned by institutional investors.
Daxor Stock Down 1.0%
Shares of Daxor stock traded down $0.10 during trading on Friday, hitting $10.30. 530 shares of the stock were exchanged, compared to its average volume of 1,786. The stock’s fifty day moving average is $10.35 and its 200 day moving average is $10.75. Daxor has a 12 month low of $8.56 and a 12 month high of $14.76.
Analyst Ratings Changes
Check Out Our Latest Stock Report on DXR
Daxor Company Profile
Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.
In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.
Featured Stories
- Five stocks we like better than Daxor
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.
